SIOX Sio Gene Therapies Inc

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will present and participate in 1-on-1 investor meetings at the UBS Global Healthcare Virtual Conference taking place May 24-26, 2021.

Details on the presentation can be found below.

Date:	Monday, May 24, 2021
Time:	10:00 AM ET
Participation Format:	Company presentation
Presenter:	Pavan Cheruvu, MD, Chief Executive Officer
Webcast:	Click here

About Sio Gene Therapies

Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com.

Contacts:

Media

Josephine Belluardo, Ph.D.LifeSci Communications(646) 751-4361jo@lifescicomms.com info@siogtx.com 

Investors and Analysts

Parag V. Meswani, PharmDSio Gene Therapies Inc.Chief Commercial Officerinvestors@siogtx.com